行情

IRWD

IRWD

Ironwood医药
NASDAQ

实时行情|Nasdaq Last Sale

11.93
-0.18
-1.45%
已收盘, 16:11 02/19 EST
开盘
12.15
昨收
12.10
最高
12.17
最低
11.66
成交量
152.87万
成交额
--
52周最高
14.10
52周最低
7.91
市值
18.87亿
市盈率(TTM)
31.75
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IRWD 新闻

  • Edited Transcript of IRWD earnings conference call or presentation 13-Feb-20 1:30pm GMT
  • Thomson Reuters StreetEvents.1天前
  • Ironwood Pharmaceuticals, Inc. (IRWD) CEO Mark Mallon on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.6天前
  • Ironwood Pharmaceuticals EPS beats by $0.07, beats on revenue
  • seekingalpha.6天前
  • Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Beat Estimates
  • Zacks.6天前

更多

所属板块

生物技术和医学研究
+1.01%
制药与医学研究
+0.22%

热门股票

名称
价格
涨跌幅

IRWD 简况

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
展开

Webull提供Ironwood Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。